Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

558
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
558
Cancer Vaccines01:30

Cancer Vaccines

405
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
405

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bibliometric and Two-Sample Mendelian Randomization Analyses of the Causal Relationship Between Hypertension and Erectile Dysfunction.

Journal of visualized experiments : JoVE·2026
Same author

Canonical and emerging regulatory mechanisms of tissue remodeling: shared principles across organs and therapeutic opportunities.

Frontiers in immunology·2026
Same author

Preprocedural hs-CRP level predicts long-term outcomes after first radiofrequency ablation in patients with nonvalvular atrial fibrillation: Insights from the China-AF cohort.

Heart rhythm·2026
Same author

S-band thulium-doped fluorotellurite fiber amplifier with an output power of ∼31 dBm and a noise figure of ∼4.94 dB at 1490 nm.

Optics letters·2026
Same author

Mid-infrared photothermal relaxation intensity diffraction tomography for video-rate volumetric chemical imaging.

Optics express·2026
Same author

Treg cells protect astrocytes from ferroptosis after subarachnoid hemorrhage by activating the HIF-1α/Hmox1 pathway.

Frontiers in immunology·2026

Related Experiment Video

Updated: Jul 20, 2025

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
11:07

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

13.3K

Chemically programmed STING-activating nano-liposomal vesicles improve anticancer immunity.

Xiaona Chen1, Fanchao Meng1, Yiting Xu1

  • 1The First Affiliated Hospital, NHC Key Laboratory of Combined Multi-Organ Transplantation, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Zhejiang University School of Medicine, 310003, Hangzhou, Zhejiang Province, P. R. China.

Nature Communications
|July 31, 2023
PubMed
Summary

New liposomal STING agonists (SAProsomes) enhance anti-tumor immunity by targeting the tumor microenvironment (TME). This approach improves drug delivery, reduces toxicity, and promotes durable remission in mouse cancer models.

More Related Videos

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.2K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K

Related Experiment Videos

Last Updated: Jul 20, 2025

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
11:07

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

13.3K
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.2K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K

Area of Science:

  • Immunology
  • Drug Delivery
  • Oncology

Background:

  • The tumor microenvironment (TME) often suppresses immune responses, limiting the effectiveness of cancer immunotherapies like checkpoint blockade.
  • Activating the STING pathway can enhance anti-tumor immunity but systemic delivery faces challenges with off-target inflammation.

Purpose of the Study:

  • To develop novel, targeted STING agonist therapies to overcome TME-mediated immune suppression.
  • To improve the delivery and safety profile of STING agonists for enhanced cancer treatment.

Main Methods:

  • Generation of esterase-activatable pro-drugs based on the STING agonist MSA-2.
  • Incorporation of pro-drugs into liposomal vesicles (SAProsomes) for intravenous administration.
  • Efficacy screening of SAProsomes in syngeneic mouse tumor models, evaluating immune stimulation and therapeutic outcomes.

Main Results:

  • Liposomal delivery (SAProsomes) improved pharmacokinetic properties and immune-stimulating capacity compared to free pro-drugs.
  • Therapeutic success correlated with enhanced delivery to tumor and lymphoid compartments.
  • The lead candidate, SAProsome-3, induced potent inflammatory cytokine secretion, a tumoricidal immune landscape, and durable tumor remission in breast cancer and melanoma models.
  • SAProsome-3 reduced metastatic burden and demonstrated postsurgical tumor-free survival without significant systemic toxicity.

Conclusions:

  • SAProsomes represent a proof-of-principle for targeted and safer STING agonist therapy.
  • This liposomal delivery system enhances STING agonist efficacy by improving tumor targeting and reducing systemic side effects.
  • The findings support the potential of SAProsomes as a novel immunotherapeutic strategy for various cancers.